About Outpace Bio
Outpace Bio is pioneering the future of cell therapy for solid tumors by harnessing unrivaled AI-powered protein design. Our mission is to program immune cells for enhanced function inside patients, overcoming key barriers such as poor tumor access, weak survival, antigen escape, and dose-related toxicity. By creating and integrating modular, plug-and-play technology assets, we are developing cell therapies with unprecedented efficacy, transforming how engineered T cells interact with cancer and the immune system to deliver life-changing outcomes. Our multidisciplinary team of scientists, engineers, coders, and cell therapy developers works at the cutting edge of computational protein design, synthetic biology, and immunology. Together, we are reimagining how cells function to unlock novel therapeutic possibilities.Located in Seattle’s vibrant biotech hub overlooking scenic South Lake Union, Outpace Bio is led by pioneers in computational protein design and engineered cell therapies. Our culture is built on a foundation of respect and inclusion, which are fundamental to how we collaborate to revolutionize cell therapy through groundbreaking innovation rooted in rigorous science.
Our Commitment to Diversity
At Outpace Bio, we believe that the highest performing teams include people from a wide variety of backgrounds and experiences. We are committed to cultivating an open, diverse, and inclusive culture for all employees. Recognizing that the best candidates do not always match all criteria of the job description, we encourage you to apply if you think you would be a good fit for the role and are inspired by our mission to cure disease by pushing the boundaries of biology.
Our Momentum
In August 2024, Outpace Bio secured an oversubscribed $144 million Series B financing, led by RA Capital Management and supported by a premier syndicate of life science investors. This funding accelerates our pipeline of programmed T cell therapies, including our lead candidate OPB-101, a mesothelin-specific chimeric antigen receptor (CAR) T cell enhanced by Outpace’s proprietary OUTSMART™, OUTLAST™, OUTSPACER™, and OUTSAFE™ technologies. OPB-101 is advancing toward IND clearance and first dosing in 2025 for patients with advanced platinum-resistant ovarian cancers. The Series B investment also supports the expansion of our pipeline, enabling us to develop additional transformative therapies leveraging our innovative plug-and-play technology platform.
To enable this vision we are seeking a highly motivated and experienced Director/Senior Director of Project & Portfolio Management to help lead our cross-functional teams designing and advancing programmed T cell therapies into the clinic. Reporting to the Chief Business Officer, you will play a pivotal role in managing drug development projects at both preclinical and clinical stages. Partnering with Asset and Project Team Leaders, you will foster a high-performing team environment while driving the development and execution of integrated project plans across functional disciplines. As the central source of project status, you will ensure alignment, facilitate timely decision-making, and escalate challenges as needed. In addition to managing individual projects, you will contribute to building project management tools and methodologies to support initiatives across our portfolio. This role may also involve serving as an alliance manager for external partners and vendors. We’re looking for a detail-oriented problem solver who thrives in dynamic environments and is passionate about Outpace’s mission to revolutionize cell therapy. If you’re a project or program management professional eager to work on cutting-edge science with a collaborative team and grow your career, this could be the role for you.
